Melissa Bersanelli

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti et al. · Journal for ImmunoTherapy of Cancer · 2019 · 400 citations · Full text

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

Alessio Cortellini, Sebastiano Buti, Daniele Santini et al. · The Oncologist · 2019 · 214 citations · Full text

Immunology, Immunoediting, Pathology +21

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

Alessio Cortellini, Rita Chiari, Biagio Ricciuti et al. · Clinical Lung Cancer · 2019 · 174 citations

Cancer Immunosurveillance, Anti-pd1 Immunotherapy, Immunodeficiencies +9

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR -Mutated NSCLC

Melissa Bersanelli, Roberta Minari, Paola Bordi et al. · Journal of Thoracic Oncology · 2016 · 166 citations · Full text

Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer

Caroline A. Nebhan, Alessio Cortellini, Weijie Ma et al. · JAMA Oncology · 2021 · 146 citations · Full text